OneSource Specialty Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

OneSource Specialty Pharma and Formycon AG, an independent biosimilar developer headquartered in Munich, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics' facility in Bangalore.

The collaboration brings together Formycon?s Biosimilar development excellence with OneSource's end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.

OneSource Specialty Pharma announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, 560076 from 22 June 2026 to 30 June 2026.

The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.

Net profit of OneSource Specialty Pharma declined 95.33% to Rs 4.60 crore in the quarter ended March 2026 as against Rs 98.50 crore during the previous quarter ended March 2025. Sales rose 0.53% to Rs 428.22 crore in the quarter ended March 2026 as against Rs 425.95 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 73.80 crore in the year ended March 2026 as against net loss of Rs 17.97 crore during the previous year ended March 2025. Sales declined 1.61% to Rs 1421.59 crore in the year ended March 2026 as against Rs 1444.85 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

OneSource Specialty Pharma has allotted 3,150 equity shares under ESOP on 13 May 2026. With this allotment, the paid up equity share capital has increased to 114,645,801 equity shares of Re. 1/- each.